Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system

BACKGROUND: Infliximab (Remicade), a chimeric monoclonal antibody against human TNFα, will inevitably face competition from biosimilar products, because of its effectiveness in autoimmune diseases and rapidly increasing market demand. According to guidelines for biosimilar development, the “biosimil...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Drug Des Devel Ther
Autores principales: An, Qing, Zheng, Yingxin, Zhao, Yirong, Liu, Tao, Guo, Huaizu, Zhang, Dapeng, Qian, Weizhu, Wang, Hao, Guo, Yajun, Hou, Sheng, Li, Jing
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2019
Materias:
Clinical Trial Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6420106/
https://ncbi.nlm.nih.gov/pubmed/30880912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S170913
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares